{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:46:48Z","timestamp":1793652408535,"version":"4.5.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T00:00:00Z","timestamp":1646524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T00:00:00Z","timestamp":1646524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00592-022-01866-3","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T06:02:39Z","timestamp":1646546559000},"page":"783-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-8569","authenticated-orcid":false,"given":"Mainak","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimesh","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satinath","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,6]]},"reference":[{"key":"1866_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50:S11\u2013S16. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.008","journal-title":"Semin Arthritis Rheum"},{"key":"1866_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431\u20131446. https:\/\/doi.org\/10.1002\/acr.21772","journal-title":"Arthritis Care Res"},{"key":"1866_CR3","doi-asserted-by":"publisher","first-page":"19520","DOI":"10.1038\/srep19520","volume":"6","author":"M Li","year":"2016","unstructured":"Li M, Hu X, Fan Y et al (2016) Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose\u2013response meta-analysis. Sci Rep 6:19520. https:\/\/doi.org\/10.1038\/srep19520","journal-title":"Sci Rep"},{"key":"1866_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122. https:\/\/doi.org\/10.1186\/1471-2369-15-122","journal-title":"BMC Nephrol"},{"key":"1866_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11926-017-0688-y","volume":"19","author":"GE Thottam","year":"2017","unstructured":"Thottam GE, Krasnokutsky S, Pillinger MH (2017) Gout and metabolic syndrome: a tangled web. Curr Rheumatol Rep 19:60. https:\/\/doi.org\/10.1007\/s11926-017-0688-y","journal-title":"Curr Rheumatol Rep"},{"key":"1866_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"key":"1866_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378:1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"key":"1866_CR8","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","volume":"1","author":"J Li","year":"2019","unstructured":"Li J, Badve SV, Zhou Z et al (2019) The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol 1:e220\u2013e228. https:\/\/doi.org\/10.1016\/S2665-9913(19)30078-5","journal-title":"Lancet Rheumatol"},{"key":"1866_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14559","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Inzucchi SE, Mattheus M et al (2021) Empagliflozin and uric acid metabolism in diabetes: a post-hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab dom. https:\/\/doi.org\/10.1111\/dom.14559","journal-title":"Diabetes Obes Metab dom"},{"key":"1866_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/M19-2610","volume":"172","author":"M Fralick","year":"2020","unstructured":"Fralick M, Chen SK, Patorno E, Kim SC (2020) Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 172:186. https:\/\/doi.org\/10.7326\/M19-2610","journal-title":"Ann Intern Med"},{"key":"1866_CR11","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pds.5252","volume":"30","author":"LC Lund","year":"2021","unstructured":"Lund LC, H\u00f8jlund M, Henriksen DP et al (2021) Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf 30:1391\u20131395. https:\/\/doi.org\/10.1002\/pds.5252","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1866_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35353","volume":"4","author":"M-C Chung","year":"2021","unstructured":"Chung M-C, Hung P-H, Hsiao P-J et al (2021) Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open 4:e2135353. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35353","journal-title":"JAMA Netw Open"},{"key":"1866_CR13","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700\u2013b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"1866_CR14","first-page":"29","volume":"10","author":"J Higgins","year":"2016","unstructured":"Higgins J, Sterne J, Savovic J et al (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10:29\u201331","journal-title":"Cochrane Database Syst Rev"},{"key":"1866_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"1866_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/13548506.2019.1707241","volume":"25","author":"R Zhao","year":"2020","unstructured":"Zhao R, Wang Y, Fu T et al (2020) Gout and risk of diabetes mellitus: meta-analysis of observational studies. Psychol Health Med 25:917\u2013930. https:\/\/doi.org\/10.1080\/13548506.2019.1707241","journal-title":"Psychol Health Med"},{"key":"1866_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi HK, Mount DB, Reginato AM (2005) Pathogenesis of Gout. Ann Intern Med 143:499. https:\/\/doi.org\/10.7326\/0003-4819-143-7-200510040-00009","journal-title":"Ann Intern Med"},{"key":"1866_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5470739","volume":"2020","author":"X Li","year":"2020","unstructured":"Li X, Li L, Xing Y et al (2020) Diabetes mellitus is associated with a lower risk of gout: a meta-analysis of observational studies. J Diabetes Res 2020:1\u201312. https:\/\/doi.org\/10.1155\/2020\/5470739","journal-title":"J Diabetes Res"},{"key":"1866_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D et al (2018) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 20:458\u2013462. https:\/\/doi.org\/10.1111\/dom.13101","journal-title":"Diabetes Obes Metab"},{"key":"1866_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391\u2013404. https:\/\/doi.org\/10.1002\/bdd.1909","journal-title":"Biopharm Drug Dispos"},{"key":"1866_CR21","first-page":"4186","volume":"21","author":"M Cutolo","year":"2017","unstructured":"Cutolo M, Cimmino MA, Perez-Ruiz F (2017) Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Eur Rev Med Pharmacol Sci 21:4186\u20134195","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1866_CR22","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","volume":"8","author":"SJ Mancini","year":"2018","unstructured":"Mancini SJ, Boyd D, Katwan OJ et al (2018) Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep 8:5276. https:\/\/doi.org\/10.1038\/s41598-018-23420-4","journal-title":"Sci Rep"},{"key":"1866_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.7326\/M18-1167","volume":"169","author":"DH Solomon","year":"2018","unstructured":"Solomon DH, Glynn RJ, MacFadyen JG et al (2018) Relationship of interleukin-1\u03b2 blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med 169:535. https:\/\/doi.org\/10.7326\/M18-1167","journal-title":"Ann Intern Med"},{"key":"1866_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T et al (2020) 2020 American college of rheumatology guideline for the management of gout. Arthritis Rheumatol 72:879\u2013895. https:\/\/doi.org\/10.1002\/art.41247","journal-title":"Arthritis Rheumatol"},{"key":"1866_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16:380\u2013390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1","journal-title":"Nat Rev Rheumatol"},{"key":"1866_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.dsx.2020.01.007","volume":"14","author":"R Valsaraj","year":"2020","unstructured":"Valsaraj R, Singh AK, Gangopadhyay KK et al (2020) Management of asymptomatic hyperuricemia: integrated diabetes & endocrine academy (idea) consensus statement. Diabetes Metab Syndr Clin Res Rev 14:93\u2013100. https:\/\/doi.org\/10.1016\/j.dsx.2020.01.007","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"1866_CR27","doi-asserted-by":"publisher","first-page":"105530","DOI":"10.1016\/j.phrs.2021.105530","volume":"166","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Trevisan R, Perseghin G (2021) Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines. Pharmacol Res 166:105530. https:\/\/doi.org\/10.1016\/j.phrs.2021.105530","journal-title":"Pharmacol Res"},{"key":"1866_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/postgradmedj-2015-133691","volume":"92","author":"A Collier","year":"2016","unstructured":"Collier A, Stirling A, Cameron L et al (2016) Gout and diabetes: a common combination. Postgrad Med J 92:372\u2013378. https:\/\/doi.org\/10.1136\/postgradmedj-2015-133691","journal-title":"Postgrad Med J"},{"key":"1866_CR29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","volume":"21","author":"CJ Bailey","year":"2019","unstructured":"Bailey CJ (2019) Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab 21:1291\u20131298. https:\/\/doi.org\/10.1111\/dom.13670","journal-title":"Diabetes Obes Metab"},{"key":"1866_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027817","volume":"6","author":"H Ito","year":"2011","unstructured":"Ito H, Abe M, Mifune M et al (2011) Hyperuricemia Is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS ONE 6:e27817. https:\/\/doi.org\/10.1371\/journal.pone.0027817","journal-title":"PLoS ONE"},{"key":"1866_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1042\/CS20200580","volume":"134","author":"M Su","year":"2020","unstructured":"Su M, Sun L, Li W et al (2020) Metformin alleviates hyperuricaemia\u2013induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging. Clin Sci 134:1537\u20131553. https:\/\/doi.org\/10.1042\/CS20200580","journal-title":"Clin Sci"},{"key":"1866_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","volume":"63","author":"M Takir","year":"2015","unstructured":"Takir M, Kostek O, Ozkok A et al (2015) Lowering Uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med 63:924\u2013929. https:\/\/doi.org\/10.1097\/JIM.0000000000000242","journal-title":"J Investig Med"},{"key":"1866_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet 396:819\u2013829. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9","journal-title":"The Lancet"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-022-01866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-022-01866-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-022-01866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T03:46:59Z","timestamp":1652154419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-022-01866-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1007\/s00592-022-01866-3","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,6]]},"assertion":[{"value":"11 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}